The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like.

On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to acquire Emalex Biosciences. The transaction involves $700 million in cash, plus up to $200 million in milestone payments and royalties. Through the acquisition, the company gains access to ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. Following positive Phase 3 results, ecopipam awaits an NDA in the second half of 2026. The transaction is anticipated to close by Q3 2026, with Teva Pharmaceutical Industries Limited (NYSE:TEVA) maintaining its 2027 financial targets despite the near-term investment.

Separately, Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its Q1 2026 earnings results on April 29, 2026, highlighting a 2% increase in revenue year-over-year to approximately $4 billion in USD. The company attributes the increase to its innovative portfolio growth and disciplined execution, despite facing headwinds in lenalidomide capsules. The company’s non-GAAP EPS of $0.53 surpassed the consensus estimate of $0.48 – $0.50.

Druckenmiller built a multi-quarter position on the stock before trimming in Q4 2025, while Cramer reversed his long-held skepticism and hosted the CEO in January 2026, praising a genuine turnaround.

The company brought in a new leader, Richard Francis, at the beginning of 2023, and the stock hasn’t looked back since, nearly 400% gain from its 2022 lows.

Founded in 1901, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a leading innovative biopharmaceutical company. The Israel-based company focuses on developing, manufacturing, marketing, and distributing generic and other medicines and biopharmaceutical products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 New Contenders for S&P 500 Index and Harvard University Stock Portfolio: Top 10 Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.